Health Care·Pharmaceuticals·$3.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.21 | N/A | +39.06% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.21 | N/A | +39.06% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management remains positive about the future of their pipeline. However, they did not provide specific guidance for the upcoming quarters.
Management expressed confidence in ongoing projects despite not providing specific guidance.
They highlighted the importance of upcoming clinical trials.
Nektar Therapeutics reported a narrower-than-expected loss per share, which was a positive surprise for investors. However, the lack of revenue details and no guidance led to a slight decline in the stock price. The market may be cautious as investors await more information on the company's future prospects.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
RB GLOBAL INC
Feb 26, 2018